rna
interfer
rnai
sequencespecif
posttranscript
gene
silenc
techniqu
develop
dramat
increas
util
scientif
therapeut
purpos
short
interf
rna
sirna
current
exploit
regul
protein
express
relev
mani
therapeut
applic
commonli
use
tool
elucid
diseaseassoci
gene
osteoporosi
associ
osteoporot
fragil
fractur
men
women
rapidli
becom
global
healthcar
crisi
averag
life
expect
increas
worldwid
new
therapeut
need
increas
patient
popul
review
describ
divers
molecular
target
suitabl
rnaibas
gene
knockdown
osteoclast
control
osteoclastmedi
excess
bone
resorpt
identifi
strategi
develop
target
sirna
deliveri
effici
gene
silenc
describ
opportun
challeng
introduc
sirna
therapeut
approach
hard
connect
tissu
disord
current
treatment
osteoporosi
divid
two
categori
antiresorpt
modul
anabol
therapi
estrogen
estrogen
receptor
modul
calcitonin
bisphosphon
fall
first
categori
one
anabol
agentteriparatidei
clinic
approv
administr
daili
inject
limit
number
option
antiresorpt
therapi
reflect
inadequ
efficaci
sever
side
effect
high
dose
frequenc
low
patient
complianc
estrogen
treatment
exhibit
known
side
effect
breast
uteru
inappropri
longterm
use
longterm
calcitionin
treatment
induc
toler
sinc
half
patient
produc
circul
antibodi
calcitionin
bisphosphon
common
current
osteoporosi
treatment
exhibit
gener
side
effect
includ
gastrointestin
irrit
bonejoint
pain
jaw
osteonecrosi
latter
two
advers
effect
persist
even
spread
new
area
unaffect
bone
fdaapprov
denosumab
demonstr
preced
success
regard
transient
efficaci
sirna
mean
turn
facilit
transient
program
benefit
notabl
sirna
new
target
distinct
drug
class
uniqu
characterist
interrupt
intrins
cellular
pathway
high
target
specif
normal
bone
constantli
replac
resorpt
old
bone
osteoclast
deposit
new
bone
osteoblast
continu
bone
turnov
result
adult
human
skeleton
complet
replac
everi
year
balanc
bone
turnov
tightli
regul
healthi
individu
shown
figur
osteoclast
resid
near
bone
surfac
multinucl
phagocyt
cell
form
fusion
monocyt
macrophag
precursor
cell
respons
resorb
bone
work
togeth
osteoblast
bone
produc
cell
play
central
role
normal
bone
remodel
two
cytokin
nuclear
factor
kappa
b
rank
ligand
rankl
also
call
tranceopglodf
macrophag
colonystimul
factor
mcsf
essenti
process
shown
figur
previous
publish
evid
show
osteoclast
format
stimul
vitro
use
cocultur
bone
marrow
cell
stromal
cellsosteoblast
express
two
cytokin
mcsf
interact
cfm
receptor
provid
signal
necessari
precursor
cell
surviv
prolifer
receptor
bind
earli
osteoclast
precursor
cell
rankl
key
cytokin
promot
osteoclastogenesi
interact
solubl
rankl
rank
receptor
surfac
osteoclast
precursor
essenti
express
osteoclastspecif
gene
bone
resorpt
surviv
matur
osteoclast
furthermor
osteoclastogenesi
neg
regul
opg
osteoclastogenesi
inhibitori
factor
ocif
also
express
stromal
cell
osteoblast
opg
decoy
receptor
compet
rank
bind
rankl
osteoclast
product
block
overexpress
opg
result
osteopetrosi
mice
ranklrankopg
regulatori
axi
posit
regul
rankl
neg
regul
opg
coordin
interact
rank
regul
normal
bone
format
degrad
rank
therefor
central
factor
bone
metabol
regulatori
pathway
central
much
osteoclast
function
phenotyp
bone
metabol
balanc
therefor
rank
chosen
knockdown
target
suppress
osteoclastmedi
bone
resorpt
select
knockdown
rank
mous
bone
marrow
cell
significantli
block
format
tartrat
resist
acid
phosphatas
trap
posit
cell
rankl
mcsf
vitro
cellcel
fusion
inhibit
rank
sirnatransfect
osteoclast
consist
fact
rankl
stimul
critic
cell
fusion
osteoclast
success
transfect
seen
matur
osteoclast
osteoclastmedi
bone
resorpt
dramat
inhibit
rank
sirna
use
pit
format
assay
vitro
activ
rank
rankl
induc
osteoclast
differenti
surviv
also
lead
activ
bone
resorpt
matur
osteoclast
activ
differenti
osteoclast
move
target
matrix
attach
bone
surfac
attach
isol
extracellular
microenviron
call
seal
zone
form
interfac
underli
bone
osteoclast
membran
activ
gener
osteoclast
osteoclast
polar
form
ruffl
membran
adjac
bone
surfac
resorpt
organel
seal
zone
osteoclast
acidifi
dissolv
underli
bone
matrix
pump
hydrogen
ion
mediat
vacuolar
h
adenosin
triphosphatas
h
atpas
ruffl
membran
seal
zone
osteoclast
intracellular
ph
maintain
hco
cl
exchang
across
cell
surfac
ruffl
membran
area
ion
transport
event
result
acid
ph
within
resorpt
microenviron
miner
phase
bone
first
digest
acid
milieu
follow
degrad
collagenrich
deminer
organ
compon
bone
releas
hydrolyt
enzym
bone
matrix
degrad
protein
taken
osteoclast
ruffl
membran
resorpt
lacuna
releas
basolater
membran
extracellular
space
local
bone
resorpt
complet
site
osteoclast
detach
bone
matrix
migrat
new
site
begin
next
function
cycl
central
role
bone
process
osteoclast
natur
major
target
studi
seek
suppress
bone
resorpt
review
sirna
target
osteoporosi
sort
three
categori
osteoclastogenesi
osteoclast
bone
resorpt
activ
osteoclast
surviv
includ
potenti
associ
target
identifi
date
addit
progress
develop
effici
target
silenc
deliveri
issu
emerg
opportun
challeng
exploit
sirna
therapeut
purpos
discuss
transcript
factor
essenti
osteoclastogenesi
includ
rank
mediat
osteoclast
differenti
inflammatori
osteolysi
osteoclast
differenti
failur
report
caus
mutant
mice
upstream
regul
kinas
ikk
complex
contain
catalyt
subunit
regulatori
subunit
requir
normal
bone
homeostasi
essenti
osteoclastogenesi
osteoclast
surviv
sinc
delet
impair
osteoclast
differenti
vitro
vivio
ikk
alpha
mice
show
overal
skelet
defect
ikk
alpha
hematopoiet
cell
fail
differenti
multinucl
osteoclast
nonetheless
role
unclear
recent
transient
transfect
sirna
inhibit
bone
marrowderiv
osteoclast
precursor
report
use
retrovir
deliveri
approach
knock
format
multinucl
osteoclast
reduc
compar
control
addit
role
confirm
observ
ranklinduc
osteolysi
imped
prevent
oligomer
monom
use
peptid
mice
studi
suggest
essenti
osteoclastogenesi
thu
three
ikk
subunit
could
potenti
target
inhibit
osteoclastogenesi
osteolysi
use
sirna
interact
rankl
rank
essenti
osteoclastogenesi
rank
three
tnf
receptorassoci
factor
bind
site
recruit
activ
transcript
factor
activ
nuclear
factor
activ
cell
demonstr
transcript
factor
strongli
induc
activ
also
known
import
immun
respons
also
play
essenti
role
osteoclastogenesi
therefor
sirna
target
raw
cell
rawinduc
osteoclast
lp
stimul
examin
specif
knockdown
led
reduc
format
matur
osteoclast
significantli
decreas
osteoclastspecif
gene
express
includ
trap
cathepsin
k
respons
effect
osteoclast
bone
resorpt
rank
activ
ligand
sever
signal
cascad
induc
osteoclast
format
activ
result
activ
sever
transcript
factor
mediat
protein
kinas
cfo
cjun
transcript
factor
cjun
recent
shown
essenti
role
osteoclastogenesi
interact
rank
rankl
stimul
jnk
activ
cjun
complex
cfo
downstream
form
moreov
cjun
report
regul
osteoclastogen
activ
dominantneg
cjun
transgen
mice
unabl
form
osteoclast
due
arrest
activ
express
nfat
famili
protein
recent
use
proteom
approach
member
famili
growth
regulatori
gene
found
highli
induc
rankl
activ
capabl
regul
cjun
activ
use
rna
silenc
technolog
knockdown
result
significantli
reduc
express
cjun
less
trapposit
multinucl
cell
compar
control
furthermor
overexpress
enhanc
cjun
phosphoryl
therefor
function
downstream
rankrankl
signal
upstream
cjun
osteoclastogen
regul
dendrit
cellspecif
transmembran
protein
dcstamp
seven
subunittransmembran
protein
origin
found
dendrit
cell
highli
express
osteoclast
macrophag
express
level
dcstamp
rapidli
upregul
ranklmedi
osteoclastogenesi
osteoclast
precursor
use
sirna
specif
knock
express
rawd
cell
complet
abrog
format
multinucl
osteoclastlik
cell
stimul
rankl
vitro
consist
osteoclastogenesi
also
enhanc
overexpress
dcstamp
vice
versa
addit
dcstamp
proven
essenti
osteoclast
foreign
bodi
giant
cell
fusion
multinuclear
osteoclast
observ
bone
section
dcstampdefici
mice
mononuclear
cell
unabl
differenti
multinuclear
osteoclast
stimul
rankl
mcsf
vitro
remain
mononuclear
trapposit
cell
cell
abl
resorb
bone
much
lower
effici
exhibit
pathogenesi
moder
osteopetrosi
consist
result
bone
miner
densiti
bone
volum
per
tissu
volum
mice
increas
compar
wild
type
control
dcstamp
therefor
conclud
indispens
osteoclast
multinucl
novel
gene
bear
signific
similar
dcstamp
famili
call
osteoclast
stimulatori
transmembran
protein
ocstamp
identifi
primari
bone
marrow
cell
cell
strongli
upregul
respons
rankl
stimul
multipl
transmembran
protein
osteoclast
block
ocstamp
express
either
rna
interfer
ocstamp
antibodi
show
similar
result
block
dcstamp
mononuclear
trapposit
cell
result
suggest
dcstamp
ocstamp
respons
cell
fusion
compens
sinc
knockdown
one
impair
osteoclast
multinucl
studi
aim
protect
biomateri
inhibit
macrophag
fusion
implant
site
show
use
sirna
target
limit
fusion
without
limit
phagocytosi
studi
attempt
find
fusion
target
share
foreign
bodi
giant
cell
form
monocyt
fusion
also
osteoclast
osteoclast
format
theoret
inhibit
well
studi
requir
confirm
effect
silenc
monocyt
fusion
osteoclast
membran
glycoprotein
one
tetraspanin
report
play
import
role
cell
fusion
osteoclastogenesi
report
involv
cellcel
fusion
cell
motil
differ
cell
raw
cell
locat
cell
membran
express
upregul
rankl
stimul
target
inhibit
use
sirna
abl
significantli
inhibit
format
raw
differenti
osteoclast
inhibit
cell
fusion
cultur
overexpress
interestingli
promot
cell
fusion
raw
cultur
without
rankl
stimul
fuse
cell
trapneg
studi
confirm
express
osteoclast
vivo
immunohistochem
analysi
tissu
section
mous
femor
bone
osteoclastogenesi
cellcel
fusion
process
sialic
acid
involv
number
biolog
respons
hypothes
play
role
process
takahata
etal
found
alpha
linkedsial
acid
degrad
osteoclast
differenti
desialyl
cell
could
form
mononuclear
trap
cell
normal
express
osteoclast
marker
use
sirna
knock
alpha
sialyltransferas
produc
signific
inhibit
osteoclast
multinucl
suggest
role
alpha
linkedsial
acid
cellcel
fusion
process
osteoclastogenesi
novel
gene
significantli
upregul
ranklstimul
osteoclast
precursor
murin
orthologu
human
gene
encod
cationproton
antiport
cpa
local
mitochondria
propos
regul
proton
concentr
osteoclast
mitochondria
select
express
differenti
osteoclast
regul
na
depend
mitochondri
ph
chang
mitochondri
passiv
swell
importantli
sirna
inhibit
trapposit
multinucl
cell
format
resorpt
activ
rankl
stimul
reduct
partial
result
apoptosi
induc
loss
inhibit
activ
therefor
integr
involv
osteoclast
format
resorpt
surviv
ovarian
cancer
gproteincoupl
receptor
histidineenrich
protonsensor
gene
found
upregul
long
bone
osteopetrot
rat
inject
compar
untreat
mutant
express
also
induc
raw
cell
rankl
stimul
osteoclast
differenti
specif
knock
express
sirna
produc
almost
inhibit
osteoclast
format
mous
bone
marrow
mononuclear
raw
cell
without
signific
cell
death
concomit
confirm
role
regul
osteoclastogenesi
express
function
regul
gprotein
signal
rg
protein
osteoclastogen
rankl
signal
cascad
investig
rg
protein
suggest
physiolog
regul
gprotein
cycl
g
protein
signal
hematopoiet
cell
protein
famili
specif
express
hematopoiet
cell
show
consist
decreas
mrna
express
level
rankl
stimul
osteoclastogenesi
targetspecif
knockdown
cell
use
sirna
result
enhanc
osteoclast
format
rankl
induct
addit
antibodi
zn
ion
addit
antagonist
significantli
revers
effect
sirna
observ
suggest
abil
suppress
osteoclastogenesi
depend
signal
pathway
inhibit
cell
signal
anoth
rg
member
report
significantli
upregul
rankl
stimul
express
dosedepend
rankl
use
vectorbas
rnai
technolog
stabl
raw
cell
show
time
lower
number
trapposit
multinucl
cell
rankl
stimul
compar
control
group
mechan
complet
block
osteoclast
differenti
suggest
lie
regul
intracellular
ca
oscil
pathway
differenti
ca
oscil
complet
block
express
simultan
significantli
inhibit
rg
cell
trigger
receptor
express
myeloid
produc
myeloid
cell
bone
marrow
locat
cell
surfac
interact
produc
tyrobp
gene
transmit
signal
activ
cell
osteoclast
precursor
cell
harvest
mice
form
mononuclear
trapposit
cell
stimul
rankl
mcsf
cell
exhibit
abil
resorb
bone
compar
wild
type
cell
sirna
cell
larg
reduc
number
trapposit
cell
small
nuclei
mononucl
cell
thu
signal
play
import
role
osteoclast
differenti
rankl
stimul
studi
block
murin
primari
cellinduc
osteoclast
use
antibodi
show
decreas
bone
resorpt
provid
evid
signal
also
regul
osteoclast
function
extend
space
flight
caus
sever
bone
loss
astronaut
due
micrograv
compar
normal
graviti
micrograv
acceler
osteoclastogenesi
gene
express
profil
raw
cell
micrograv
condit
shown
increas
express
calciumbind
protein
sirna
knockdown
raw
cell
significantli
suppress
osteoclastogenesi
micrograv
condit
could
therapeut
target
prevent
bone
loss
extend
space
flight
retinoblastoma
proteininteract
zinc
finger
protein
also
particip
ranklinduc
osteoclastogenesi
bind
retinoblastoma
protein
estrogen
receptor
reportedli
involv
osteosarcoma
express
increas
rankl
induct
hour
sirnatransfect
raw
cell
show
significantli
inhibit
activ
day
postrankl
mcsf
treatment
signific
influenc
express
thu
suggest
posit
regul
activ
last
stage
osteoclastogenesi
raw
cell
reduc
express
exhibit
substanti
reduc
abil
form
trapposit
multinucl
osteoclastlik
cell
rankl
mcsf
stimul
recent
cabl
domainbind
recogn
key
regul
ranklinduc
osteoclastogenesi
regul
sever
immunoreceptor
signal
pathway
immun
cell
b
nk
cell
report
promot
activ
nfat
b
cell
knockdown
raw
cell
decreas
express
complet
suppress
ranklinduc
trapposit
multinucl
cell
format
famili
disintegrin
metalloproteinas
adam
peptid
cell
surfac
protein
involv
cell
adhes
cell
fusion
transmembran
glycoprotein
express
monocyt
significantli
upregul
osteoclastogenesi
recent
shown
promot
osteoclastogenesi
wherebi
vitamin
oh
stimul
osteoclast
format
inhibit
antisens
treatment
direct
effect
osteoclastogenesi
also
investig
use
sirna
silenc
cell
decreas
osteoclast
format
cell
size
compar
control
modestli
decreas
osteoclast
marker
mrna
level
stimul
rankl
contrast
transfect
cultur
increas
osteoclast
marker
mrna
express
level
increas
number
trapposit
cell
studi
also
show
highli
express
rheumatoid
arthriti
ra
pannu
macrophag
multinucl
cell
adjac
erod
cartilag
therefor
recommend
target
suppress
ra
progress
prevent
osteoclast
format
epiderm
growth
factor
receptor
egfr
focu
increas
attent
osteoclast
bone
resorpt
shown
promot
bone
resorpt
vitro
inhibit
vitro
result
suppress
bone
marrow
stromal
cell
induc
osteoclast
differenti
yi
et
al
investig
egfr
function
osteoclast
format
surviv
found
egfr
express
highli
upregul
rankl
knockdown
egfr
bone
marrow
monocyt
use
lentiviru
express
shrna
complet
suppress
osteoclastogenesi
rankl
mcsf
addit
egfr
sirna
block
express
complet
rankl
stimul
studi
also
show
egfr
coimmunoprecipit
rank
mediat
rank
signal
cascad
data
impli
egfr
may
coupl
rank
via
signal
mediat
regul
rankstimul
downstream
pathway
play
import
role
osteoclastogenesi
multinucl
osteoclast
form
fusion
monocyt
macrophag
therefor
role
integrin
import
traffick
monocyt
osteoclastogenesi
assess
use
sirna
two
integrin
pair
found
preosteoclast
monocyt
consid
premier
marker
preosteoclast
antibodi
block
primari
cell
cultur
significantli
inhibit
osteoclastogenesi
antibodi
specif
knockdown
use
sirna
raw
cell
yield
decreas
express
result
reduct
osteoclast
area
inhibit
suggest
occur
earli
stage
cell
differenti
sinc
accompani
threefold
increas
mrna
express
level
major
regul
osteoclastogenesi
taken
togeth
integrin
suggest
play
import
role
earli
stage
osteoclast
differenti
via
preosteoclast
cellcel
interact
new
member
tnf
famili
induc
cell
apoptosi
call
tnfrelat
apoptosisinduc
ligand
trail
share
amino
acid
homolog
rankl
report
inhibit
osteoclastogenesi
human
peripher
blood
mononuclear
cell
pbmc
cell
possibl
inhibit
pathway
also
involv
human
osteoclast
apoptosi
recent
trail
found
inhibit
accumul
rankldepend
pbmc
cyclindepend
kinas
inhibitor
shown
progress
upregul
play
import
role
mediat
ranklinduc
murin
osteoclastogenesi
addit
trail
preosteoclast
cultur
incub
rankl
mcsf
result
decreas
format
trapposit
cell
signific
reduct
express
use
sirna
specif
knock
pbmc
cultur
dramat
reduc
format
trapposit
cell
induc
rankl
mcsf
consist
result
defici
mice
taken
togeth
function
alon
appear
essenti
ranklmedi
osteoclastogenesi
osteoclast
mobil
bone
miner
phase
sever
hydrolyt
enzym
degrad
organ
bone
compon
princip
proteas
involv
process
cathepsin
k
lysosom
proteas
mainli
express
osteoclast
releas
ruffl
membran
resorpt
lacuna
seal
zone
cathepsin
k
mrna
protein
express
level
stimul
rankl
timeand
dosedepend
manner
increas
osteoclast
differenti
activ
cathepsin
k
effici
degrad
type
ii
collagen
gene
mutat
caus
osteopetrosi
exhibit
featur
pycnodystosi
specif
downregul
cathepsin
k
mrna
express
decreas
number
area
bone
pit
without
significantli
chang
cell
viabil
unchang
osteoclast
number
may
benefit
mainten
bone
homeostasi
sinc
osteoclast
osteoblast
activ
close
correl
disrupt
commun
may
caus
issu
matur
osteoclast
cathepsin
k
express
increas
rankl
vitro
vivo
rankrankl
bind
activ
least
five
distinct
downstream
signal
pathway
act
critic
adaptor
bind
cytoplasm
domain
rank
mutat
caus
osteopetrosi
activ
transcript
factor
suggest
result
signal
heterodimer
protein
compos
jun
cjun
junb
jund
fo
transfect
raw
cell
either
domin
neg
form
cfo
sirna
either
cjun
junb
downregul
ranklmedi
cathepsin
k
gene
express
transfect
inhibit
ctsk
promot
activ
suggest
stimul
cathepsin
k
promot
addit
cfo
known
play
critic
role
osteoclastogenesi
overexpress
cfo
rescu
ranklinduc
osteoclast
format
previous
block
n
ndimethylderythrosphingosin
treatment
h
atpas
osteoclast
ruffl
membran
respons
reduc
maintain
low
ph
seal
resorpt
lacuna
process
osteoclastmedi
extracellular
acidif
atpas
multipl
subunit
one
subunit
isoform
locat
ruffl
membran
subunit
report
highli
express
essenti
osteoclast
resorpt
function
defect
subunit
vacuolar
proton
pump
induc
sever
osteopetrosi
hu
et
al
show
success
carrierfre
sirna
transfect
primari
rat
osteoclast
cultur
report
actin
ring
structur
characterist
activ
resorb
osteoclast
reduc
control
sirna
transfect
reemerg
halt
transfect
bone
resorpt
pit
significantli
reduc
hr
transfect
type
collagen
ctermin
crosslink
telopeptid
cultur
media
decreas
compar
control
nontarget
sirna
treat
group
h
atpas
knockdown
similar
cathepsin
k
knockdown
specif
gene
downregul
reduc
osteoclast
resorpt
activ
without
induc
cell
death
h
atpas
two
domain
locat
cytoplasm
side
bound
within
membran
atphydrolyt
domain
individu
subunit
ah
subunit
c
murin
h
atpas
three
isoform
highli
express
osteoclast
compar
two
highli
upregul
rankl
mcsf
stimul
differenti
feng
et
al
deplet
express
murin
bone
marrow
macrophag
signific
differ
number
trapposit
multinucl
cell
compar
untreat
cultur
howev
osteoclast
abil
activ
produc
h
acidifi
extracellular
seal
zone
environ
larg
impair
area
resorpt
pit
dentin
slice
sirnatr
osteoclast
control
cultur
coimmunoprecipit
studi
show
interact
anoth
essenti
ruffl
border
h
atpas
subunit
coloc
microtubul
distinct
defici
deplet
abl
impair
factin
ring
format
therefor
suggest
regul
factin
seal
ring
format
osteoclast
activ
taken
togeth
knockdown
affect
osteoclastogenesi
inhibit
osteoclast
bone
resorpt
electrostat
neutral
membran
potenti
gradient
osteoclast
acid
secret
maintain
cl
ion
channel
osteoclast
ruffl
border
cl
channel
highli
express
osteoclast
local
ruffl
border
membran
disrupt
human
mice
produc
sever
osteopetrosi
except
clc
famili
channel
identifi
osteoclast
function
cl
ionspecif
channel
intracellular
organel
endosom
lysosom
organel
acid
bone
resorpt
activ
reduc
use
sirna
okamoto
et
al
conclud
observ
osteoclast
bone
resorpt
reli
intern
organel
acidif
sinc
locat
intracellular
organel
influenc
organel
acid
exclus
howev
bone
resorpt
activ
remain
absenc
activ
osteoclast
attribut
role
redund
cl
ion
channel
sinc
caus
sever
osteopetrosi
chlorid
channeldefici
mice
function
role
k
cl
cotransport
kcc
mous
osteoclastmedi
bone
resorpt
focu
kcc
exist
mani
tissu
cell
transport
k
cl
ion
driven
respect
individu
chemic
gradient
previou
studi
show
mrna
express
murin
osteoclast
locat
cell
membran
kcc
inhibitor
r
butylindazon
dioa
abl
increas
intracellular
concentr
cl
h
resorb
osteoclast
thu
inhibit
kcc
suppress
cl
secret
resorb
osteoclast
eventu
produc
reduc
h
pump
activ
transfect
bone
marrow
cellinduc
osteoclast
sirna
dramat
reduc
area
bone
resorpt
pit
compar
control
result
similar
slightli
less
potent
inhibit
na
ca
ion
exchang
ncx
bidirect
membran
transport
regul
ca
homeostasi
mani
tissu
cell
plasma
membran
ncx
famili
compris
homolog
protein
ncx
ncx
ncx
murin
osteoclast
three
splice
variant
call
detect
ncx
mediat
ca
efflux
influx
predict
locat
ruffl
border
control
ca
influx
resorb
osteoclast
sirna
deliv
mous
bone
marrow
cellinduc
osteoclast
significantli
reduc
area
bone
resorpt
pit
per
osteoclast
approxim
data
support
essenti
role
three
ncx
ca
transport
import
role
regul
bone
resorpt
csrc
gene
encod
cytosol
protein
tyrosin
kinas
ptk
also
essenti
osteoclast
activ
lack
csrc
express
mice
result
osteopetrosi
character
inact
osteoclast
previou
work
indic
csrc
function
adaptor
osteoclast
regul
cell
attach
migrat
recruit
essenti
signal
protein
strong
csrc
ptk
activ
found
ruffl
border
activ
osteoclast
osteoclastmedi
bone
resorpt
abolish
vivo
vitro
block
csrc
ptk
activ
osteoclast
knockdown
src
express
raw
cell
reduc
size
number
actin
ring
decreas
cell
spread
fusion
rate
csrc
ptk
activ
activ
dephosphoryl
structur
uniqu
osteoclastspecif
transmembran
proteintyrosin
phosphatas
ptpoc
osteoclast
known
osteoclastlik
precursor
cell
transfect
ptpoc
sirna
serumcontain
media
show
ranklmedi
suppress
osteoclast
differenti
osteoclast
number
size
significantli
reduc
decreas
endogen
ptpoc
mrna
level
addit
apoptosi
induc
significantli
ptpoc
sirna
compar
control
sirna
enhanc
apoptosi
knockdown
also
suggest
role
osteoclast
addit
ptpoc
also
indic
involov
regul
ranklmedi
osteoclast
differenti
homolog
recombin
strategi
use
inhibit
ptpoc
function
cell
cultur
ptpoc
knockout
cell
could
form
trapposit
multinucl
osteoclastlik
cell
rankl
treatment
day
therefor
ptpoc
target
matur
osteoclast
inhibit
bone
resorpt
also
osteoclast
precursor
limit
differenti
osteoclast
osteoclast
seal
zone
requir
tight
attach
osteoclast
bone
surfac
success
bone
resorpt
depend
upon
format
dens
beltlik
actin
ring
surround
ruffl
membran
osteoclast
actin
ring
high
concentr
actin
filament
assembl
local
dynam
structur
podosom
bone
attach
site
signific
prerequisit
role
osteoclast
bone
resorpt
actin
ring
format
target
inhibit
osteoclast
investig
mani
studi
gelsolin
import
actin
regul
necessari
podosom
format
necessari
actin
ring
format
mean
gelsolinnul
osteoclast
abl
resorb
bone
reduc
potenc
howev
wiscottaldrich
syndrom
protein
wasp
critic
podosom
assembl
exist
actin
ring
gelsolinnul
osteoclast
wasp
interact
phosphatidylinositol
pip
respons
integrin
signal
enhanc
seal
zone
format
bone
resorpt
mice
without
wasp
express
exhibit
defect
format
podosom
actin
ring
seal
zone
bone
format
attenu
wasp
use
sirna
demonstr
absenc
podosom
format
actin
ring
reduc
bone
resorpt
wasp
activ
coordin
bind
pip
full
activ
stimul
actinnucl
function
actinrel
protein
arp
complex
associ
complex
initi
actin
nucleat
crosslink
report
upregul
raw
cell
respons
rankl
knockdown
ranklstimul
raw
cell
use
sirna
gener
averag
protein
reduct
hour
posttransfect
fewer
podosomelik
structur
appear
compar
control
less
actin
ring
observ
knockdown
prove
vital
role
actin
ring
format
potenti
new
target
therapeut
agent
actin
nucleat
requir
phosphoryl
wasp
ctermin
vca
domain
wasp
bind
complex
integr
number
signal
ptppest
proteintyrosin
phosphataseprolin
glutam
acid
serin
threonin
amino
acid
sequenc
shown
involv
wasp
src
phosphoryl
dephosphoryl
regul
phosphoryl
protein
associ
wasp
enhanc
interact
wasp
actin
monom
complex
increas
wasp
conform
stabil
time
regul
src
activ
de
phosphoryl
reduc
ptppest
express
level
use
sirna
osteoclast
elimin
actin
ring
significantli
inhibit
format
seal
zone
format
complex
bone
resorpt
indic
direct
role
ptppest
format
cellseal
zone
interact
wasp
simultan
wasp
cortactin
csrc
substrat
bind
ntermin
acid
domain
promot
actin
assembl
stabil
actin
filament
bind
repeat
region
cortactin
found
hematopoiet
cell
precursor
induc
differenti
osteoclast
deplet
cortactin
primari
mous
osteoclast
use
sirna
result
absenc
podosom
seal
ring
loss
boneresorb
abil
suggest
indispens
role
cortactin
osteoclast
bone
resorpt
cortactin
mechan
regul
seal
ring
format
studi
instead
inhibit
initi
actin
aggreg
phase
knockdown
cortactin
use
sirna
suppress
subsequ
seal
zone
matur
process
osteoclast
abil
attach
bone
surfac
essenti
success
bone
resorpt
intracellular
calcium
channel
involv
regul
revers
osteoclast
attach
bind
endosom
isoform
cgmpdepend
kinas
substrat
irag
use
sirna
irag
human
osteoclast
vitro
reduc
cell
spread
diamet
display
distribut
podosom
loss
podosom
ring
structur
explain
reduc
cell
adhes
knockdown
orphan
nuclear
receptor
raw
cell
gener
similar
effect
irag
express
osteopontin
integrin
subunit
downregul
silenc
transfect
cell
detach
substrat
easili
podosom
belt
observ
though
cell
adhes
migrat
impair
differenti
precursor
cell
prolifer
influenc
knockdown
given
essenti
role
actin
assembl
osteoclast
bone
resorpt
motor
protein
famili
myosin
respons
actinbas
motil
examin
osteoclast
myosin
x
maintain
low
express
level
vertebr
tissu
bind
actin
microtubul
assembl
podosom
seal
zone
osteoclast
depend
complet
intact
microtubul
system
rnaimedi
inhibit
mous
bone
marrowderiv
osteoclast
reduc
size
seal
zone
cell
perimet
influenc
cell
fusion
braintyp
creatin
kinas
ckb
exhibit
high
upregul
upon
osteoclast
matur
wit
proteom
technolog
increas
express
occur
mice
bone
marrow
cell
cell
expos
rankl
mcsf
ckb
regul
atp
distribut
suppli
cell
requir
osteoclast
actin
format
mainten
downregul
ckb
cell
cultur
produc
promin
reduct
area
resorpt
pit
dentin
slice
reduc
resorpt
abil
suggest
partial
due
impair
actin
ring
structur
observ
transfect
osteoclast
addit
ckb
also
shown
affect
vatpas
activ
major
proton
pump
essenti
osteoclast
resorpt
normal
osteoclast
recov
intracellular
ph
challeng
strong
acid
second
howev
lack
intercellular
ph
recoveri
observ
inhibit
ckb
infer
ckb
influenc
osteoclast
bone
resorpt
affect
vatpas
vitro
cell
cultur
data
confirm
vivo
reduc
bone
surfac
eros
ovarectom
ckb
mice
interestingli
signific
differ
number
osteoclast
observ
ckb
wildtyp
mice
therefor
ckb
target
alter
osteoclast
activ
osteoclastogenesi
addit
target
osteoclastogenesi
osteoclast
bone
resorpt
target
induct
osteoclast
apoptosi
also
effici
strategi
suppress
excess
bone
loss
egfr
target
regul
osteoclast
differenti
mention
section
inhibit
egfr
express
also
report
caus
apoptosi
matur
osteoclast
pathway
inhibit
activ
taken
togeth
sirna
egfr
inhibit
osteoclast
differenti
also
suppress
matur
osteoclast
surviv
rank
sirna
similarli
character
ranklrank
interact
respons
osteoclast
differenti
bone
resorpt
matur
osteoclast
surviv
well
therefor
matur
osteoclast
transfect
rank
sirna
result
cell
death
taken
togeth
transfect
either
osteoclast
precursor
matur
osteoclast
rank
sirna
reduc
osteoclastmedi
bone
resorpt
inhibit
osteoclast
differenti
resorpt
activ
osteoclast
surviv
bisphosphon
commonli
use
pharmacolog
approach
target
osteoporosi
current
sever
side
effect
cloud
therapeut
efficaci
altern
sirna
alendron
nitrogencontain
bisphosphon
nbp
known
molecular
target
farnesyl
pyrophosph
synthas
fpp
investig
inhibit
osteoclast
promot
osteoblast
activ
simultan
fpp
play
import
role
mevalon
pathway
produc
lipid
essenti
cell
surviv
addit
nbp
report
induc
human
osteoblast
differenti
miner
cultur
inhibit
mevalon
pathway
sirna
target
fpp
significantli
suppress
osteoclast
cell
viabil
singl
transfect
significantli
increas
osteoblast
differenti
effect
sustain
day
posttransfect
osteoblast
howev
treatment
significantli
chang
osteoblast
prolifer
miner
compar
control
therefor
select
knockdown
fpp
express
potenti
inhibit
osteoclast
time
promot
osteoblast
activ
sirna
target
describ
influenc
osteoclast
surviv
well
mention
target
osteoclastogenesi
inhibit
osteoclast
resorpt
activ
partial
reduc
express
induc
apoptosi
loss
inhibit
activ
signific
osteoclast
death
also
induc
sirna
transfect
section
sirna
structur
uniqu
osteoclastspecif
transmembran
ptpoc
induc
signific
apoptosi
osteoclastlik
precursor
cell
section
addit
mani
gener
cell
apoptosi
signal
report
use
sirna
target
protein
regul
parthway
cellspecif
deliveri
essenti
avoid
undesir
side
effect
recognit
bone
osteoclast
regul
cell
integrin
receptor
integrin
calciumdepend
heterodimer
transmembran
protein
receptor
mediat
cell
attach
extracellular
matrix
cell
four
differ
integrin
activ
express
osteoclast
among
highli
express
osteoclast
exhibit
import
role
facilit
osteoclast
attach
bone
subsequ
bone
resorpt
process
osteoclastmedi
bone
resorpt
shown
significantli
inhibit
antibodi
treatment
vitro
increas
skelet
mass
absenc
actin
ring
abnorm
osteoclast
ruffl
membran
observ
osteoclast
mice
integrin
recogn
extracellular
rgd
peptid
sequenc
therefor
rgd
peptid
use
label
target
cell
vivo
addit
inhibit
use
solubl
rgd
mimic
receptor
antagonist
reduc
osteoclast
bone
resorpt
vitro
vivo
suggest
blockad
prevent
rapid
bone
loss
caus
estrogen
withdraw
studi
seek
identifi
human
peripher
blood
monocyt
subset
differenti
osteoclast
subunit
sirna
transfect
human
monocyt
transfect
significantli
reduc
trapposit
multinucl
cell
dosedepend
manner
silenc
subunit
myeloma
cell
human
patient
suppress
bone
resorpt
activ
ie
osteoclastlik
activ
cell
vitro
data
reflect
import
integrin
subunit
ranklinduc
osteoclastogenesi
therefor
could
attract
target
attenu
modul
osteoclast
bone
resorpt
solubl
cell
signal
protein
well
known
protect
cell
malign
tumor
transform
coordin
sever
intracellular
signal
network
ubiquitin
ligas
murin
doubl
minut
regul
activ
control
halflif
recent
small
molecul
inhibitor
nutlin
report
competit
bind
interrupt
interact
activ
pathway
order
investig
effect
preosteoclast
precursor
cell
surviv
prolifer
differenti
human
peripher
blood
mononuclear
cell
preosteoclast
transfect
sirna
result
show
antiosteoclastogenesi
activ
greatli
compromis
sirna
indic
inhibitori
effect
osteoclast
precursor
requir
activ
pathway
use
sirna
technolog
interrupt
interact
may
therefor
therapeut
implic
control
excess
osteoclast
activ
mention
vida
supra
possibl
target
control
osteoclastogenesi
sevenpass
transmembran
protein
bind
proton
exhibit
phsens
activ
given
increas
extracellular
proton
concentr
led
nuclear
transloc
downstream
mediat
rankl
stimul
osteoclast
role
still
unclear
could
link
bone
ph
homeostasi
work
proton
sensor
respons
extern
acidosi
therefor
studi
investig
function
bone
resorpt
site
necessari
valid
target
osteoclastmedi
excess
bone
resorpt
fpp
use
sirna
target
inhibit
osteoclast
viabil
mimick
pharmacolog
nbp
vida
supra
howev
deplet
intracellular
geranylgeranyl
pyrophosph
ggpp
also
report
produc
analog
phenotyp
effect
bisphosphon
treatment
osteoclast
osteoblast
therefor
sirna
inhibit
ggpp
synthas
may
induc
apoptosi
osteoclast
simultan
promot
osteoblast
activ
use
sirna
ggpp
synthas
could
also
potenti
suppress
excess
bone
loss
stimul
osteoblast
bone
product
osteoclast
form
cell
fusion
celltocel
contact
critic
osteoclastogenesi
cell
adhes
molecul
intercellular
adhes
whose
express
regul
intracellular
signal
jnk
involv
cellcel
contact
osteoclast
precursor
osteoblastsstrom
cell
among
osteoclast
precursor
bind
integrin
pair
block
interact
inhibit
osteoclast
format
hidetaka
et
al
report
sirna
knockdown
cell
effect
osteoclastogenesi
altern
could
sirna
target
inhibit
osteoclast
express
osteoclast
precursor
matur
osteoclast
also
osteoblast
therefor
cellspecif
target
deliveri
essenti
specif
bioactiv
sirna
select
osteoclast
desir
rnai
novel
therapeut
approach
consider
potenti
silenc
abnorm
gene
especi
gene
target
effect
target
convent
therapeut
ie
small
molecul
protein
antibodi
major
obstacl
develop
sirna
therapeut
also
target
deliveri
clinic
accept
formul
reliabl
rout
administr
particularli
true
sirna
deliveri
bone
intrins
poor
drug
penetr
vascular
perfus
bone
primarili
compos
three
cell
type
osteoclast
osteoblast
osteocyt
bone
uniqu
extracellular
matrix
strongli
miner
calcium
phosphat
form
wt
apatit
major
reservoir
bodi
calcium
activ
involv
physiolog
calcium
phosphoru
homeostasi
increas
molecular
cellular
understand
bone
biolog
produc
continu
report
new
potenti
therapeut
target
variou
bone
patholog
nonetheless
despit
new
target
identifi
osteoclastspecif
target
method
yet
reliabl
tissuebas
specif
requisit
bonespecif
necessari
therapeut
agent
seriou
complic
crossreact
nontarget
tissu
poor
efficaci
due
low
drug
target
tissu
concentr
requir
reliabl
target
strategi
mani
attempt
improv
target
drug
bone
miner
fraction
apatit
includ
drug
conjug
bonetarget
ligand
tetracyclin
estradiol
bisphosphon
bisphosphon
especi
nbp
antiresorpt
drug
intrins
high
affin
bone
apatit
surfac
attract
deliveri
conjug
nonspecif
bone
therapeut
agent
howev
exploit
bonetarget
agent
must
consid
free
bisphosphon
also
increas
antiresorpt
activ
sirna
well
known
short
circul
halfliv
vivo
unmodifi
nake
sirna
directli
administ
directli
vivo
exhibit
min
halflif
system
administr
rat
due
degrad
serum
nucleas
mani
studi
seek
overcom
challeng
sirna
deliveri
chemic
modif
sirna
nucleotid
lipidliposomalpolymerbas
complex
collagen
atelocollagen
base
formul
sirna
well
viral
vector
polymercomplex
sirna
carrier
method
advantag
disadvantag
nonvir
deliveri
consid
clinic
relev
deliveri
mechan
avoid
known
problem
current
viral
vector
deliveri
high
viral
toxic
possibl
carcinogen
proven
immunogen
signific
cost
limit
deliveri
sirna
target
specif
bone
entir
new
stori
date
vivo
sirna
studi
human
focus
rheumatoid
arthriti
ra
local
deliveri
intraarticular
inject
electropor
sirna
topic
cream
system
deliveri
modest
effect
deliveri
sirna
bone
osteoclast
vivo
either
target
address
yet
report
improv
sirna
stabil
vivo
variou
chemic
modif
investig
sirna
stabil
nucleas
degrad
improv
introduc
phosphorothio
ps
backbon
linkag
modifi
ribos
posit
well
modif
show
signific
improv
unmodifi
sirna
combin
modif
result
substanti
improv
sirna
bioactiv
plasma
stabil
improv
sirna
plasma
stabil
facilit
reliabl
system
dose
versatil
deliveri
option
addit
specif
sirna
chemic
modif
potenti
use
improv
conjug
target
well
bonetarget
ligand
antibodi
small
molecul
drug
vida
supra
conjug
sirna
molecul
variou
chemistri
system
deliveri
sirnabas
bone
diseas
therapeut
exampl
bisphosphon
conjug
ribos
hydroxyl
group
sirna
sugar
modif
ribos
end
guid
sirna
strand
appear
effect
improv
sirna
activ
case
bisphosphon
perform
drug
also
target
moieti
deliv
sirna
specif
bone
use
tissuespecif
target
method
local
system
deliv
sirna
reliabl
dose
judici
combin
home
molecul
concept
sirna
target
improv
system
local
efficaci
shown
figur
establish
drug
deliveri
strategi
util
target
system
local
sirna
deliveri
includ
sirna
conjug
cell
membranetarget
ligand
antibodi
watersolubl
polym
cellpenetr
peptid
method
seek
improv
amount
sirna
deliv
specif
target
bone
cell
limit
drug
offtarget
effect
cell
osteoclast
rank
express
osteoclast
precursor
well
matur
osteoclast
serv
popular
molecular
target
osteoporosi
therapi
antibodi
rank
test
effect
osteoclast
target
conjug
calcitonin
antiresorpt
protein
drug
conjug
show
efficaci
inhibit
osteoclast
format
bone
resorpt
strategi
use
receptor
ligand
bind
peptid
target
moieti
provid
gener
approach
gener
osteoclasttarget
platform
specif
drug
deliveri
osteoclast
osteoclastspecif
protein
also
util
purpos
cathepsin
k
addit
mani
calciumbind
protein
recent
review
includ
acid
prolinerich
salivari
protein
osteocalcin
sialoprotein
osteopontin
potenti
novel
bonetarget
moieti
hexapeptid
asp
exhibit
high
affin
bone
use
bonetarget
moieti
conjug
estradiol
ovariectom
mice
conjug
maintain
bone
densiti
similarli
unconjug
estradiol
without
display
increas
liver
uteru
weight
addit
specif
chemic
modif
protect
sirna
plasma
also
provid
formul
sirna
nanomacros
particl
deliveri
recent
review
drug
deliveri
strategi
date
primarili
target
liver
either
deliber
nondiscrimin
natur
result
firstpass
metabol
highli
effici
liverbas
drug
colloid
clearanc
advantag
liver
target
therapi
exampl
hydrodynam
tailvein
inject
fa
sirna
success
protect
mice
liver
failur
fibrosi
howev
liver
reticuloendotheli
mpsre
system
tissu
effici
filter
drug
carrier
particl
ie
despit
activ
target
target
tissu
site
avoid
massiv
dose
remov
local
deliv
sirnaparticl
formul
use
bonetarget
therapeut
specif
target
osteoclast
osteoclast
precursor
sirna
deliveri
exploit
drug
carrier
particl
sizeselect
cellspecif
uptak
numer
phagocyt
target
cell
bone
tissu
use
local
deliveri
context
osteoporosi
therapi
target
cell
preosteoclast
monocyt
osteoclast
natur
phagocyt
cell
phagocyt
effici
take
particl
diamet
howev
particl
diamet
greater
nm
larg
penetr
nonphagocyt
cell
membran
ie
osteoblast
fibroblast
either
passiv
endocytosi
pinocytosi
therefor
sirnaload
microparticl
control
size
could
exploit
select
intern
osteoclast
phagocyt
mechan
target
sirna
cell
new
osteoporot
therapeut
strategi
without
conjug
target
moieti
particl
could
deliv
local
bone
site
clinic
case
especi
bone
augment
implant
surgeri
addit
bone
molecular
drug
target
appropri
osteoclast
osteoblast
sirnacontain
nanoparticl
capabl
taken
cell
type
might
effect
increas
bone
mass
inhibit
osteoclast
simultan
stimul
osteoblast
particl
opsonis
host
plasma
protein
commonli
problem
drug
carrier
may
confound
target
cell
phagocytosi
sinc
opsonis
particularli
nonspecif
adsorpt
immunoglobulin
complement
onto
particl
may
activ
macrophag
tcell
caus
inflamm
surround
tissu
damag
healthi
cell
current
local
sirna
administr
effici
system
deliveri
shortterm
therapeut
purpos
nonetheless
local
deliveri
must
also
consid
target
specif
exampl
intraarticular
inject
sirna
ra
effect
rout
administr
transfect
osteoclast
locat
near
bone
surfac
common
osteoporot
bone
site
notabl
pelvi
vertebra
wrist
maxim
drug
avail
specif
bone
site
obtain
reliabl
reproduc
predict
pharmcokinet
profil
bioactiv
materi
includ
porou
chitosancollagen
scaffold
inject
fdaapprov
calcium
phosphat
bone
cement
cpc
develop
drug
carrier
local
bone
deliveri
polymethylmethacryl
pmma
bone
cement
use
clinic
implant
fixat
kyphoplasti
bone
augment
exhibit
poor
control
entrap
dose
releas
kinet
often
leav
drug
trap
pmma
inject
cpc
exhibit
sever
uniqu
properti
bone
drug
deliveri
includ
periop
prepar
drug
load
liquidsolid
set
situ
intrins
osteoconduct
degrad
osteoclast
osteoinduct
infiltr
osteoblast
replac
new
bone
accept
biocompat
cpc
selfset
abil
ambient
bodi
temperatur
within
bone
caviti
enabl
inject
formul
larg
expand
therapeut
util
date
larg
bodi
evid
support
feasibl
valu
use
cpc
local
drug
carrier
bone
augment
pharmacolog
activ
molecul
readili
dispers
distribut
throughout
cpc
prior
set
surgic
placement
provid
sustain
control
drug
releas
medium
sever
convent
small
molecul
proteinbas
drug
deliv
use
cpc
bone
includ
antibiot
decreas
postsurg
infect
anticanc
drug
reduc
tumorogenesi
growth
factor
promot
bone
heal
therefor
despit
limit
mechan
properti
cpc
could
also
use
deliv
sirna
bone
local
deliveri
matrix
degrad
cation
hydrogel
compris
gelatin
chitosan
use
local
deliveri
antisens
oligonucleotid
target
murin
suppress
endotoxininduc
osteolysi
mous
calvaria
cation
polymer
chitosan
complex
anion
nucleotid
also
facilit
cell
transfect
osteoclast
number
bone
resorpt
significantli
suppress
week
postimplant
idea
also
extend
sirna
local
deliveri
bone
intrins
low
ph
osteoclast
resorpt
lacuna
cell
lysosom
attract
basi
target
drug
conjug
carrier
contain
acidcleav
hydrazon
bond
addit
variou
acidsensit
cathepsin
kspecif
mmpsspecif
peptid
linkag
review
recent
also
provid
diseaseand
environment
specif
bonetarget
strategi
appropri
target
sirna
bone
deliveri
first
clinic
trial
involv
sirna
appli
local
intraocular
inject
patient
choroid
neovascular
cnv
cnv
agerel
eye
disord
character
choroid
vessel
invas
retina
beneath
retin
pigment
epithelium
nake
sirna
target
vegfa
show
signific
suppress
laserinjuryinduc
cnv
mice
model
howev
new
data
show
therapeut
suppress
gener
sirnaclass
effect
independ
sirna
sequenc
observ
therapi
base
interact
cellsurfac
endosom
tolllik
receptor
cell
membran
doublestrand
viral
rna
sensor
found
numer
cell
type
sirna
regardless
rna
sequenc
target
intern
howev
bind
sirna
nucleotid
longer
requir
form
conjug
play
indispens
role
trif
cell
signal
cascad
trif
adaptor
protein
import
discoveri
reveal
gener
properti
sirna
vascular
tissu
improv
global
understand
sirna
gener
bioactiv
desir
potenti
undesir
nonspecif
signal
pathway
regard
primari
human
choroid
endotheli
cell
show
decreas
surviv
serumcontain
media
cultur
serumst
omethyllussirna
without
transfect
reagent
extracellular
sirnainduc
cytotox
might
affect
organ
includ
bone
osteoclast
precursor
matur
osteoclast
express
poli
c
dsrna
act
ligand
stimul
cell
surfac
produc
strong
inhibit
osteoclast
differenti
mous
bone
marrow
cultur
human
peripher
blood
monocyt
ugml
dosedepend
manner
induct
mcsf
rankl
tlr
stimul
induc
product
variou
proinflammatori
cytokin
prompt
high
level
phagocyt
activ
osteoclast
precursor
indic
enhanc
immun
respons
tlr
stimul
osteoclast
precursor
taken
togeth
unanticip
vascular
immunegener
sirnaclass
effect
care
consid
sirna
therapi
especi
deliv
system
gene
silenc
use
sirna
mani
potenti
therapeut
applic
due
sever
advantag
intrins
rnai
high
target
specif
intrins
biolog
respons
effect
sirna
deliveri
select
target
desir
tissu
site
remain
problemat
sirna
deliveri
bone
develop
rel
slowli
compar
deliveri
tissu
regard
osteoporosi
increasingli
challeng
problem
global
need
improv
therapeut
mani
new
cellular
target
osteoclast
continu
report
attract
sirna
knockdown
effici
sirna
deliveri
method
select
target
bone
connect
tissu
osteoclast
must
develop
improv
optim
sirna
efficaci
bioavail
therapeut
durat
context
osteoclastmedi
excess
bone
resorpt
larg
unexplor
strategi
attract
option
develop
new
therapeut
author
acknowledg
support
nih
grant
normal
bone
metabol
homeostasi
balanc
bone
resorpt
deposit
mechan
balanc
goe
awri
osteoporosi
patholog
concept
therapeut
sirna
target
deliveri
improv
sirna
bioavail
therapeut
efficaci
